Cytokinetics' Aficamten Shows Strong Efficacy in nHCM, Plans Q4 FDA Filing
CYTK has more than doubled off its 52-week low of $35.22.
Summary
Detailed Phase 3 data for aficamten in non-obstructive HCM (nHCM) showed 53% of patients achieved meaningful improvement in at least three of five key disease areas versus 13% on placebo. The company plans a supplemental U.S. marketing application in Q4 2026, expanding the drug's label beyond its current oHCM approval. Safety concerns include a 10% rate of dangerous drops in heart pumping capacity and 12 heart failure events, which management attributes to the trial's rigid dosing algorithm. Barclays forecasts over $5 billion in peak sales for Myqorzo, and Bristol Myers will start a rival nHCM study later this year. This follows the July UK approval and the ongoing patent lawsuit against Bristol Myers, adding both opportunity and competitive pressure. The results were presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2026 and published in The New England Journal of Medicine.
At the time of this announcement, CYTK was trading at $78.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8B. The 52-week trading range was $35.22 to $88.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.